Skip to Content

Naglazyme Side Effects

Generic Name: galsulfase

Note: This page contains side effects data for the generic drug galsulfase. It is possible that some of the dosage forms included below may not apply to the brand name Naglazyme.

In Summary

Common side effects of Naglazyme include: severe infusion related reaction, conjunctivitis, rigors, chest pain, development of igg antibodies, dyspnea, infusion related reaction, otalgia, pain, and pharyngitis. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to galsulfase: intravenous solution

As well as its needed effects, galsulfase (the active ingredient contained in Naglazyme) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking galsulfase, check with your doctor or nurse immediately:

Less common:
  • Blurred or decreased vision
  • chest pain
  • difficult or labored breathing
  • dizziness
  • headache
  • hernia of the naval
  • nervousness
  • pounding in the ears
  • slow or fast heartbeat
  • swelling of the face
  • tightness in the chest
Incidence not known:
  • Back pain
  • bluish lips or skin
  • confusion
  • cough
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fever, chills, or sweating
  • hives or welts
  • joint pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of bladder control
  • loss of bowel control
  • nausea or vomiting
  • paralysis of the limbs
  • stomach pain

Minor Side Effects

Some galsulfase side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Diarrhea
  • ear pain
  • loss of appetite
Less common:
  • Body aches or pain
  • burning, dry, or itching eyes
  • congestion
  • dryness or soreness of the throat
  • excessive tearing
  • loss of or increase in reflexes
  • runny or stuffy nose
  • tender, swollen glands in the neck
  • trouble with swallowing
  • unusual tiredness or weakness
  • voice changes
Incidence not known:
  • Difficulty with moving
  • loss of voice
  • muscle pain or stiffness
  • sneezing

For Healthcare Professionals

Applies to galsulfase: intravenous solution


The most frequently reported adverse reactions included rash, pain, urticaria, pyrexia, pruritus, chills, headache, nausea, vomiting, abdominal pain, and dyspnea.

The most frequently reported adverse reactions requiring interventions are infusion-related reactions.[Ref]


Frequency not reported: Anaphylaxis/anaphylactoid reaction, allergic reaction[Ref]


Very common (10% or more): Rash (21%), angioedema, urticaria, pruritus
Common (1% to 10%): Erythema[Ref]


Very common (10% or more): Abdominal pain (47%), gastroenteritis (11%), umbilical hernia (11%), nausea, vomiting[Ref]


Very common (10% or more): Infusion reactions (56%), ear pain (42%), pain (32%), chills/rigors (21%), chest pain (16%), malaise (11%), hearing impairment (11%), pyrexia[Ref]

Infusion reactions, which occurred in 56% of patients across 5 clinical studies were defined as adverse reactions occurring during infusions or until the end of the infusion day. Infusion reactions were observed as early as week 1 and as late as week 146 of treatment and occurred during multiple infusions, however, not always in consecutive weeks. The most common signs/symptoms included pruritus, vomiting, abdominal pain, nausea, hypertension, headache, chest pain, erythema, cough, hypotension, angioedema, respiratory distress, tremor, conjunctivitis, malaise, bronchospasm, and arthralgia.[Ref]


Very common (10% or more): Hypertension (11%)
Common (1% to 10%): Hypotension
Frequency not reported: Pallor, bradycardia, tachycardia, cyanosis, shock[Ref]

Nervous system

Very common (10% or more): Areflexia (11%), headache
Common (1% to 10%): Tremor
Frequency not reported: Paresthesia[Ref]


Very common (10% or more): Dyspnea (21%), pharyngitis (11%), nasal congestion (11%)
Common (1% to 10%): Apnea, cough, respiratory distress, asthma, bronchospasm
Frequency not reported: Laryngeal edema, hypoxia, tachypnea, sleep apnea
Postmarketing reports: Respiratory failure[Ref]


Very common (10% or more): Arthralgia (42%)[Ref]


Very common (10% or more): Conjunctivitis (21%), corneal opacity (11%)[Ref]


Very common (10% or more): Development of antidrug antibodies (98%)[Ref]

During clinical trials, 53 out of 54 patients tested positive for antidrug IgG antibodies within 4 to 8 weeks of treatment. In the placebo controlled study, 19 patients were evaluated for a potential relationship between development of antidrug antibodies to clinical outcome measures. While all 19 patients developed antidrug antibodies, there was no consistent predictive relationship between total antibody titer, neutralizing or IgE antibodies, and infusion-associated reactions, urinary glycosaminoglycan (GAG) levels, or endurance measures.[Ref]


Postmarketing reports: Membranous nephropathy[Ref]


Postmarketing reports: Thrombocytopenia[Ref]


1. Cerner Multum, Inc. "Australian Product Information." O 0

2. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL:"

3. "Product Information. Naglazyme (galsulfase)." BioMarin Pharmaceutical Inc, Novato, CA.

It is possible that some side effects of Naglazyme may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.